ATE119380T1 - Dosiereinheit für die perkutane absorption analgetischer oder antagonistischer narkotika. - Google Patents

Dosiereinheit für die perkutane absorption analgetischer oder antagonistischer narkotika.

Info

Publication number
ATE119380T1
ATE119380T1 AT87906005T AT87906005T ATE119380T1 AT E119380 T1 ATE119380 T1 AT E119380T1 AT 87906005 T AT87906005 T AT 87906005T AT 87906005 T AT87906005 T AT 87906005T AT E119380 T1 ATE119380 T1 AT E119380T1
Authority
AT
Austria
Prior art keywords
analgesic
polymer matrix
dosage units
absorption
percutane
Prior art date
Application number
AT87906005T
Other languages
English (en)
Inventor
Yie W Chien
Chin-Chih Chiang
Kabuji Tojo
Original Assignee
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers filed Critical Univ Rutgers
Application granted granted Critical
Publication of ATE119380T1 publication Critical patent/ATE119380T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
AT87906005T 1986-09-03 1987-09-02 Dosiereinheit für die perkutane absorption analgetischer oder antagonistischer narkotika. ATE119380T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/903,273 US4806341A (en) 1985-02-25 1986-09-03 Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration

Publications (1)

Publication Number Publication Date
ATE119380T1 true ATE119380T1 (de) 1995-03-15

Family

ID=25417212

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87906005T ATE119380T1 (de) 1986-09-03 1987-09-02 Dosiereinheit für die perkutane absorption analgetischer oder antagonistischer narkotika.

Country Status (11)

Country Link
US (1) US4806341A (de)
EP (1) EP0290482B1 (de)
JP (1) JPH02500741A (de)
KR (1) KR950012181B1 (de)
AT (1) ATE119380T1 (de)
AU (1) AU628284B2 (de)
CA (1) CA1309659C (de)
DE (1) DE3751140T2 (de)
DK (1) DK175580B1 (de)
FI (1) FI98887C (de)
WO (1) WO1988001497A1 (de)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364628A (en) * 1985-05-31 1994-11-15 Sandoz Ltd. Pharmaceutical compositions
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US4839174A (en) * 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
DE3910543A1 (de) * 1989-04-01 1990-10-11 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit erhoehtem wirkstofffluss und verfahren zu seiner herstellung
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DE3939376C1 (de) * 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
AU3595393A (en) * 1992-01-31 1993-09-01 Cygnus Therapeutic Systems Transdermal administration of buprenorphine in the form of ion pair complexes
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
CA2165802A1 (en) * 1993-09-29 1995-04-06 Eun Soo Lee Monoglyceride/lactate ester permeation enhancer for oxybutynin
DE4403709A1 (de) * 1994-02-07 1995-08-10 Lohmann Therapie Syst Lts Pharmazeutische Zusammensetzung zur systemischen transdermalen Verabreichung mit dem Wirkstoff Morphin-6-glucuronid
EP0748629A4 (de) * 1994-03-11 1997-08-20 Sekisui Chemical Co Ltd Pflaster zur perkutanen absorption, das ein säureadditionssalz von morphin enthält
JP2819236B2 (ja) * 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
US5633000A (en) * 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US5733571A (en) * 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
EP1009407B1 (de) 1997-09-04 2004-04-28 Novoneuron, Inc. Noribogain zur behandlung von schmerzen und drogenabhängigkeit
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1041987B1 (de) 1997-12-22 2006-04-19 Euro-Celtique S.A. Peroral zu verabreichende arzneiform enthaltend eine kombination von einem opioid agonisten und naltrexon
EP1041988A4 (de) 1997-12-22 2002-03-13 Euro Celtique Sa Verfahren zur vorbeugung von missbrauch von opioid-dosis-formen
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
WO2000069416A1 (en) * 1999-05-13 2000-11-23 Unihart Corporation Pharmaceutical compositions comprising apocodeine and/or its derivatives
WO2001043726A1 (en) * 1999-12-16 2001-06-21 Trident Technologies, Llc System and method for extended delivery of a therapeutic agent with its receptor loading dose
IL151058A0 (en) 2000-02-08 2003-04-10 Euro Celtique Sa Controlled-release compositions containing opioid agonist and antagonist
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP2092936B1 (de) 2000-02-08 2013-03-20 Euro-Celtique S.A. Missbrauchssichere orale Opioidagonisten-Formulierungen
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
JP4898073B2 (ja) * 2000-07-31 2012-03-14 ニュコメデ ダンマルク アンパーツセルスカブ 鼻内投与用フェンタニル組成物
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
EP1387673B1 (de) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Opioid enthaltende arzneiform gegen missbrauch
JP4302991B2 (ja) 2001-05-22 2009-07-29 ユーロ−セルティーク エス．エイ． 経皮性剤形を分配する容器及び装置
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
DK1435945T3 (da) * 2001-06-05 2008-12-01 Ronald Aung-Din Topisk migræne terapi
SI1416842T1 (sl) * 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
IL160222A0 (en) 2001-08-06 2004-07-25 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US6844438B2 (en) * 2001-08-15 2005-01-18 Mclean Hospital Corporation N-substituted derivatives of morphinan and uses thereof
CA2460352C (en) * 2001-08-17 2013-05-14 Lavipharm Laboratories Inc. Composition and transdermal drug delivery device
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
WO2003079945A1 (en) * 2002-03-20 2003-10-02 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
HUE032656T2 (en) 2002-04-05 2017-10-30 Euro Celtique Sa Pharmaceutical composition containing oxicodone and naloxone
TW200404581A (en) 2002-04-23 2004-04-01 Alza Corp Transdermal analgesic systems with reduced abuse potential
EP1513532B1 (de) 2002-06-10 2007-02-28 Euro-Celtique S.A. Entsorgungssysteme für transdermale abgabevorrichtungen zur verhinderung des missbrauchs von darin enthaltenen wirkstoffen
DK1530469T3 (da) * 2002-08-20 2009-05-04 Euro Celtique Sa Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist
CN1703200B (zh) * 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
DE60329515D1 (de) * 2002-10-25 2009-11-12 Euro Celtique Sa Analoga und prodrugs von buprenorphin
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
AU2003297073A1 (en) * 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
AU2003297074A1 (en) * 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
EP1913938A1 (de) 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermales Dosierungsschema für Buprenorphin zur Schmerzstillung
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
KR101159828B1 (ko) * 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
EP1635892A4 (de) * 2003-05-22 2008-08-27 Leading Medical Res L L C Röhrenförmige vorrichtung zum einführen in ein hohlorgan und verfahren zu ihrer bildung
US20070065463A1 (en) * 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
DK1638492T3 (da) * 2003-07-25 2008-05-13 Euro Celtique Sa Præoperativ behandling af postoperativ smerte
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
CA2543610A1 (en) * 2003-10-30 2005-05-19 Alza Corporation Transdermal analgesic systems having reduced abuse potential
HRP20090363T1 (hr) 2004-02-23 2009-08-31 Euro-Celtique S.A. Transdermalni injektor opioida rezistentan na zlouporabu
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
PT1765292T (pt) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
JP4745747B2 (ja) 2004-08-12 2011-08-10 日東電工株式会社 フェンタニル含有貼付製剤
JP4824963B2 (ja) * 2004-08-12 2011-11-30 日東電工株式会社 貼付材及び貼付製剤
DE102004044578A1 (de) 2004-09-13 2006-03-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit einer Haftschicht, Verfahren zum Silikonisieren einer Rückschicht des Systems und Verwendung der Rückschicht
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
US8246977B2 (en) 2004-10-21 2012-08-21 Durect Corporation Transdermal delivery systems
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
WO2006124585A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug system for the delivery of galantamine
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070196456A1 (en) * 2005-09-15 2007-08-23 Visible Assets, Inc. Smart patch
WO2007095147A2 (en) * 2006-02-13 2007-08-23 Aveva Drug Delivery Systems Adhesive preparation comprising sufentanil and methods of using the same
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
US20070278289A1 (en) * 2006-05-31 2007-12-06 Toshiba Tec Kabushiki Kaisha Payment adjusting apparatus and program therefor
SI2719378T1 (sl) * 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
US20080069871A1 (en) * 2006-07-21 2008-03-20 Vaughn Jason M Hydrophobic abuse deterrent delivery system
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CA2681110A1 (en) * 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2259780A2 (de) * 2008-02-28 2010-12-15 Syntropharma Limited Pharmazeutische zusammensetzung mit naltrexon
US8592424B2 (en) 2008-06-30 2013-11-26 Afgin Pharma Llc Topical regional neuro-affective therapy
EP2317991B1 (de) * 2008-07-07 2017-05-03 Euro-Celtique S.A. Verwendung von opioid-antagonisten zur behandlung von harnverhalt
KR20110071064A (ko) * 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
RU2012101792A (ru) * 2009-06-19 2013-07-27 Нопп Ньюросайенсиз, Инк. Композиции и способы для лечения бокового амиотрофического склероза
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP5927506B2 (ja) 2010-04-13 2016-06-01 レルマダ セラピューティクス、インク． １−メチル−２’，６’−ピペコロキシリダイドの皮膚医薬組成物および使用方法
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
EP2595632A1 (de) 2010-07-23 2013-05-29 DemeRx, Inc. Noribogain-zusammensetzungen
HUE034955T2 (en) 2010-12-22 2018-03-28 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
EP2481740B1 (de) 2011-01-26 2015-11-04 DemeRx, Inc. Verfahren und Zusammensetzungen zur Herstellung von Noribogain aus Voacangin
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
EP2748000B1 (de) * 2011-09-05 2020-11-18 Siegfried Ltd. Verpackungsmaterial für ein festes pharmazeutisches oder nutrazeutisches produkt
CA2855994A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
JP2015509075A (ja) 2011-12-09 2015-03-26 デメレックス， インコーポレイテッド ノルイボガインの硫酸エステル
TW201338813A (zh) 2011-12-12 2013-10-01 洛曼治療系統股份有限公司 經皮遞送系統
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US8877921B2 (en) 2012-01-25 2014-11-04 Demerx, Inc. Synthetic voacangine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US9783535B2 (en) 2012-12-20 2017-10-10 Demerx, Inc. Substituted noribogaine
JP6370802B2 (ja) 2012-12-28 2018-08-08 テイコク ファーマ ユーエスエー インコーポレーテッド 持続性ブプレノルフィン経皮送達組成物およびそれの使用方法
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
CA2942638C (en) 2013-03-15 2026-03-10 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2014195352A1 (en) 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3838271B1 (de) 2013-07-12 2025-09-03 Areteia Therapeutics, Inc. Behandlung eines erhöhten spiegels von eosinophilen und/oder basophilen
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
US9345711B2 (en) 2014-02-18 2016-05-24 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
CA2989550C (en) 2014-06-18 2023-08-08 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
WO2016060122A1 (ja) * 2014-10-14 2016-04-21 久光製薬株式会社 貼付剤
AU2015353414B2 (en) 2014-11-26 2021-04-29 Demerx, Inc. Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
HK1244715A1 (zh) 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3946106A (en) * 1974-10-24 1976-03-23 G. D. Searle & Co. Microsealed pharmaceutical delivery device
JPS5759806A (en) * 1980-08-11 1982-04-10 Searle & Co Nitroglycerine pad for percutaneous administration
US4336243A (en) * 1980-08-11 1982-06-22 G. D. Searle & Co. Transdermal nitroglycerin pad
US4622218A (en) * 1982-05-18 1986-11-11 University Of Florida Testicular-specific drug delivery
US4479932A (en) * 1982-05-18 1984-10-30 University Of Florida Brain-specific drug delivery
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
ZA856002B (en) * 1984-08-10 1987-04-29 Du Pont Transdermal delivery of opioids
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4662218A (en) * 1984-11-19 1987-05-05 Hawthorne M Marion Well logging device and method
ATE77962T1 (de) * 1985-02-25 1992-07-15 Univ Rutgers Dosierungssystem fuer transdermale absorption von arzneimittelwirkstoffen.
US4690683A (en) * 1985-07-02 1987-09-01 Rutgers, The State University Of New Jersey Transdermal varapamil delivery device

Also Published As

Publication number Publication date
DE3751140D1 (de) 1995-04-13
FI98887B (fi) 1997-05-30
DK239288D0 (da) 1988-05-03
EP0290482A1 (de) 1988-11-17
WO1988001497A1 (en) 1988-03-10
KR880701536A (ko) 1988-11-03
CA1309659C (en) 1992-11-03
FI98887C (fi) 1997-09-10
JPH02500741A (ja) 1990-03-15
DK239288A (da) 1988-06-24
FI890995L (fi) 1989-03-02
KR950012181B1 (ko) 1995-10-14
FI890995A0 (fi) 1989-03-02
EP0290482B1 (de) 1995-03-08
DE3751140T2 (de) 1995-07-20
US4806341A (en) 1989-02-21
AU628284B2 (en) 1992-09-17
EP0290482A4 (en) 1990-11-28
DK175580B1 (da) 2004-12-13
AU7915087A (en) 1988-03-24

Similar Documents

Publication Publication Date Title
ATE119380T1 (de) Dosiereinheit für die perkutane absorption analgetischer oder antagonistischer narkotika.
ATE77962T1 (de) Dosierungssystem fuer transdermale absorption von arzneimittelwirkstoffen.
FI880409A0 (fi) Transdermalt absorberande doseringsenhet foer estradiol och andra estrogena steroider och administrationsfoerfarande.
ATE135924T1 (de) Transdermale estrogen/progestin-dosiereinheit und system.
US20070059351A1 (en) Transdermal patches containing a nitric oxide-donor and a second active agent and associated methods
BR9815439A (pt) Analgesia contìnua obtida com buprenorphine
ATE173162T1 (de) Medizinische vorrichtung zur verabreichung von aktivsubstanzen oder arzneistoffen in sehr niedriger dosis, insbesondere von homöopatischen arzneistoffen
US20110182972A1 (en) Low-concentration capsaicin patch and methods for treating neuropathic pain
ATE185694T1 (de) Oxybutynin zur transdermalen verabreichung
DE69019628D1 (de) Verfahren und Gegenstand zur transdermalen Administration von Dexmedetomidin.
DE59603597D1 (de) Therapeutische zubereitung zur transdermalen applikation von wirkstoffen durch die haut
US20070202155A1 (en) Low dose no donor-containing transdermal patch
PT957899E (pt) Forma de dosagem para proporcionar um medicamento numa dose crescente
ATE161735T1 (de) Pharmazeutisches mittel zur behandlung von mit herpes-zoster assoziierten schmerzen und von postherpetischen neuralgien mittels lokaler anwendung von lokalanästhetika
DE59006461D1 (de) Therapeutisches System zur verzögerten und gesteuerten transdermalen oder transmucosalen Verabreichung von Wirkstoffen (II).
DE3685696D1 (de) Melatoninhaltige mittel sowie deren verwendungen.
O'Neill The cognitive and psychomotor effects of opioid drugs in cancer pain management
PT93430A (pt) Processo para a preparacao de um sistema terapeutico transdermico para a para a aministracao de substancias activas em fases e sua utilizacao para a administracao local ou sistemica de substancias activas
DE3686256D1 (de) Transdermale arzneimitteleinzeldosis gegen angina und verfahren zu ihrer verabreichung.
Zempsky Use of topical analgesics in treating neuropathic and musculoskeletal pain
Raymond et al. Transdermal fentanyl (Duragesic): respiratory arrest in adolescents
Doozan The use of cupping as a myofascial release tool to increase iliotibial band flexibility in collegiate football athletes
Bailey et al. Effect of parenterally administered atropine on the percutaneous absorption of phencyclidine and methadone
Amass et al. Administering Twice the Daily Buprenorphine Dose Suppresses Opioid Withdrawal for 48 Hours in Opioid-Dependent Humans
NO881870L (no) Doseringsenhet for transdermal absorbsjon av narkotiske analgetiske og antagonistiske stoffer og fremgangsmaate for administrering av samme.